The FDA’s warning letters targeting telehealth marketing of compounded GLP-1 drugs identify companies, including Lovely Meds, Hello Cake, and MEDVi, and reference prescribing arrangements associated with these platforms. The disclosures raise compliance considerations for clinics and Med Spas offering GLP-1 weight-loss treatments.
Published FDA Warning Letters Reveal Telehealth Companies Cited in GLP-1 Enforcement
When the FDA issued 30 warning letters to telehealth companies, including Lovely Meds, Hello Cake, and MEDVi, for marketing compounded GLP-1 drugs, the agency cited claims it said were false or misleading. The enforcement action also draws attention to how these platforms operate, where clinicians working through medical groups conduct telehealth consultations and issue prescriptions for compounded GLP-1 medications.
Understanding Telehealth GLP-1 Models and Why Prescribing Networks Are Under Scrutiny
Compounded versions of GLP-1 medications expanded rapidly during the national shortage of semaglutide and tirzepatide, when federal compounding rules had previously permitted pharmacies and outsourcing facilities to meet patient demand amid supply disruptions. On October 2, 2024, the FDA determined the shortage of tirzepatide injection products had resolved. Additionally, the FDA confirmed that the period of enforcement discretion for compounded semaglutide injection products had ended following a federal court ruling in Outsourcing Facilities Association v. FDA. The policy changes increased attention to how GLP-1 medications are prescribed, marketed, and distributed through telehealth and clinical programs.
Warning letters published in the FDA’s public enforcement database identify several platforms cited for marketing compounded GLP-1 drugs with claims the agency said were false or misleading, including MEDVi, Lovely Meds, and Hello Cake. In a February 20, 2026, warning letter to MEDVi, the FDA stated that website materials displayed compounded semaglutide and tirzepatide products labeled with the MEDVi name and included statements such as “Same active ingredient as Wegovy and Ozempic,” which the agency reported is misleading, since compounded drugs are not FDA-approved and have not been evaluated for safety or effectiveness.
A March 12, 2026, analysis published by STAT examined the prescribing structures behind these programs and reported that telehealth platforms named in the warning letters typically do not prescribe medications themselves, instead relying on clinicians in affiliated medical groups to evaluate patients and issue prescriptions. For clinics and Med Spas offering GLP-1 weight-loss treatments, the model highlights how telehealth prescribing arrangements, marketing practices, and compounding pharmacy relationships intersect with existing compliance requirements.
Regulatory and Reporting Sources
According to a March 3, 2026, press announcement from the U.S. Food and Drug Administration, the agency issued 30 warning letters to telehealth companies for marketing compounded GLP-1 drugs with claims it said were false or misleading. A March 12, 2026, analysis published by STAT further reported that several telehealth platforms named in the letters do not prescribe medications directly; instead, they rely on clinicians working through medical groups or telehealth provider networks to evaluate patients and issue prescriptions.
Telehealth GLP-1 Program Structure and Enforcement Context
The FDA warning letters focus on marketing and compounding-related violations. These enforcement actions also highlight operational areas where clinics and Med Spas participating in telehealth GLP-1 programs should review compliance structures.
Clinics and Med Spas Relying on Third-Party Prescribing Networks
Providers partnering with telehealth platforms that use separate medical groups or provider networks operate within arrangements where responsibilities for patient evaluation, prescribing, and follow-up care are divided across entities. These structures can create accountability gaps when roles are not clearly defined.
Providers Using Asynchronous or Limited Telehealth Evaluation
Models that rely on intake forms or minimal consultations may not meet state-specific requirements for prescribing injectable medications. Providers should ensure that telehealth evaluations align with applicable standards for good-faith exams and supervision.
Clinics Aligning Marketing With Clinical Practice
Providers offering GLP-1 treatments through telehealth programs may be at risk of noncompliance if marketing claims do not reflect how care is actually delivered. Patient-facing materials should align with prescribing practices, documentation, and regulatory requirements.
Operational Considerations for Providers in Telehealth GLP-1 Programs
- Clarify accountability across telehealth platforms, prescribing clinicians, and Med Spa operations involved in GLP-1 programs.
- Standardize telehealth intake, evaluation, and follow-up protocols to ensure consistency in patient care and documentation.
- Track patient outcomes and adverse events to support clinical oversight and comply with FDA reporting requirements.
- Educate staff on how telehealth GLP-1 services are delivered, prescribed, and communicated to patients
- Evaluate third-party telehealth platforms and vendors to confirm compliance with state telehealth prescribing laws, provider licensure requirements, and scope-of-practice standards.
What to Watch in GLP-1 Telehealth Oversight
The FDA’s warning letters published earlier this month focus on marketing and compounding-related violations, while a March 12, 2026, STAT analysis reported that many telehealth platforms operate through prescribing clinicians affiliated with medical groups. These developments reflect ongoing regulatory focus on how GLP-1 treatments are marketed, prescribed, and distributed under existing federal and state requirements.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our main page.
Image Attribution: “FDA Bldg 62 – Exterior” by The U.S. Food and Drug Administration, via Wikimedia Commons, licensed under Public Domain.
